Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P29275
UPID:
AA2BR_HUMAN
Alternative names:
-
Alternative UPACC:
P29275
Background:
The Adenosine receptor A2b, encoded by the gene with accession number P29275, plays a pivotal role in cellular signaling. As a receptor for adenosine, it primarily functions through the activation of G proteins that in turn stimulate adenylyl cyclase. This process is crucial for the modulation of various physiological responses.
Therapeutic significance:
Understanding the role of Adenosine receptor A2b could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways highlights its potential as a target for pharmacological intervention in conditions where adenosine signaling is dysregulated.